Etidronate treatment for brain calcifications in Fahr disease
Part of Brain & nervous system, Genetic & congenital clinical trials.
This Phase 2 study tests whether etidronate (a medicine that affects bone-calcium handling) can help people with Fahr disease or a similar condition marked by calcium deposits in the brain. It will also check safety and whether certain tests can track changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed (or are being diagnosed) with Fahr disease or syndrome based on symptoms and a brain CT scan showing abnormal calcifications.
- Your head CT shows calcifications in specific brain areas, and the amount is higher than what’s expected for your age.
- You can take the study medicine by mouth and your esophagus works well enough to swallow it.
- Your calcium and vitamin D blood tests are not too low (they can be corrected first).
- You have no major kidney problems and you have no allergy to etidronate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a medicine to help prevent abnormal calcium (called ectopic mineralization) from building up in people with pseudoxanthoma elasticum (PXE). It aims to slow or reduce new damage over time.
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
This study looks at people who have extra calcium deposits in the brain seen on a CT scan (and also includes some relatives and healthy volunteers). It aims to better understand who has brain calcification and what it may mean, using research visits and scan-based measurements.
This early study (Phase 1/2) uses brain imaging to look for “fibrin” (a blood-clot–related protein) in people with Alzheimer’s disease and related conditions. The goal is to understand whether fibrin changes can be seen on scans and what it might mean for Alzheimer’s.
This trial studies a new imaging agent that helps doctors see brain changes related to Alzheimer's, Parkinson's, and similar conditions. The goal is to improve diagnosis and monitoring of these diseases.
This study uses a special PET/CT brain scan to look at a protein called tau in people with memory/thinking and movement disorders. The results may help researchers understand how these diseases affect the brain and improve future diagnosis or care.
Hear when a new Fahr Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.